Q-omics provides the consensus-scored RPL28P2 profile across patient tissues and cancer cell-line models. RPL28P2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RPL28P2 is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, RPL28P2 RNA expression shows 19,545 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, BLCA, and THYM as cancer lineages where RPL28P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL28P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL28P2 survival associations across molecular data types. RPL28P2 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL28P2 RNA expression–survival associations across cancer types. High RPL28P2 expression shows unfavorable associations in KIRP, LGG, UVM, SKCM and ACC, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RPL28P2 RNA expression.
This table summarizes RPL28P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL28P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL28P2 shows lower tumor expression in BRCA and higher tumor expression in BLCA, CHOL, LIHC, COAD and READ. The BLCA box plot shows higher RPL28P2 RNA expression in tumor versus normal tissue (log2 FC = +0.778, t-test p = .005).
This table shows molecular features associated with RPL28P2 in patient tissues and cancer cell lines. In patient samples, RPL28P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
